CERS Stock Risk & Deep Value Analysis
Cerus Corp
Healthcare • Medical Devices
DVR Score
out of 10
The Bottom Line on CERS
We analyzed Cerus Corp using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran CERS through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
📈CERS Performance Overview3yr weekly
Unlock CERS Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
CERS Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
About Cerus Corp (CERS)
Sector
Healthcare
Industry
Medical Devices
Market Cap Category
small
Market Cap
$309.59M
CERS Deep Value Analysis
CERS Red Flags & Warning Signs
Premium- ⚠
Further delays in RBC system clinical trials or regulatory approval process
- ⚠
Higher-than-expected cash burn leading to significant, dilutive capital raises
- ⚠
Negative outcomes from ongoing clinical studies for RBC or other pipeline products
Unlock CERS Red Flags & Risk Warnings
Premium members see every risk event we found.
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
Unlock everything for $47/yr
$79/yrSave 41%
- ✓ Catalysts, bull case, moat & red flags
- ✓ Unlimited stock analyses + alerts
- ✓ Full database, search & portfolio (50 stocks)
7-day money back · Cancel anytime
CERS Financial Health Metrics
Market Cap
$309.59M
CERS Competitive Moat Analysis
PremiumMoat Rating
Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The INTERCEPT system benefits from regulatory approvals and established clinical data, creating high switching costs for blood centers. The RBC system, if approved, would create a new, durable moat through a new standard of care and extensive IP, making it difficult for competitors to replicate.
CERS Competitive Moat Analysis
Premium unlocks moat rating, sources & durability.
CERS Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q4 2025 Earnings Report (Expected mid-March 2026)
- •Updates on S&T (Safety & Efficacy Trial) progress for RBC system (Q2-Q3 2026)
Medium-Term (6-18 months)
- •Potential submission of a BLA (Biologics License Application) for RBC system (Late 2026 / Early 2027)
- •Expansion of INTERCEPT Blood System sales into new international markets
Long-Term (18+ months)
- •FDA approval and initial commercial launch of the RBC pathogen reduction system (2028+)
- •Broad adoption of RBC system disrupting traditional blood safety market
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
CERS Bull Case: What Could Go Right
- ✓
Positive clinical trial data and regulatory progress for the RBC system.
- ✓
Decreasing cash burn rate or path to profitability becoming clearer.
- ✓
Significant adoption rates of INTERCEPT in new geographies.
Bull Case Analysis
See what could go right with Premium
Never miss a move on CERS
Create a free account to set price alerts and get notified on Telegram when CERS hits your targets.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
FAQ
What is the DVR Score for Cerus Corp (CERS)?
As of March 2, 2026, Cerus Corp has a DVR Score of 6.6 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Cerus Corp?
Cerus Corp's market capitalization is approximately $309.6M. The company operates in the Healthcare sector within the Medical Devices industry.
What ticker symbol does Cerus Corp use?
CERS is the ticker symbol for Cerus Corp. The company trades on the NGM.
What is the risk level for CERS stock?
Our analysis rates Cerus Corp's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the CERS DVR analysis updated?
Our AI-powered analysis of Cerus Corp is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 2, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.